Short answer: abdomen or thigh if you inject yourself
The Mounjaro label approves three areas, but only two of them are yours to use alone. It reads: "Inject subcutaneously in the abdomen, thigh, or have another person inject in the back of the upper arm. Rotate injection sites with each dose." None of the three absorbs better. Section 12.3 states that similar exposure was achieved in the abdomen, thigh or upper arm, so there is no site that makes Mounjaro work harder. The choice is comfort and reach. The part that genuinely matters is the rotation cycle you run inside whichever area you choose, and the cycle below is built around the four doses in a KwikPen.
Most Mounjaro site guides stop at "three places, rotate weekly, pick what is comfortable". That is true and it is not enough to act on, because it leaves out the two things that decide whether your rotation survives contact with real life: which device you are holding, and what you do when week five arrives and you cannot remember week one.
Where exactly, in inches
The label names the areas. Lilly's Instructions for Use and the standard subcutaneous technique fill in the boundaries.
- Abdomen. At least 2 inches clear of the navel in every direction. Stay off the waistband line, where clothing will rub a fresh site all day.
- Thigh. The front of the thigh, in the middle third between hip and knee. Not the inner thigh, which is thinner and more tender.
- Back of the upper arm. Only when someone else is injecting it for you. The label says so, in the dosing sentence itself.
Whichever area you use, the instruction is the same every week: "Change (rotate) your injection site each week. You may use the same area of your body but be sure to choose a different injection site in that area." Staying in the abdomen is fine. Staying on the same square inch of it is not.
Which Mounjaro device you have changes the week, not the site
Mounjaro comes in more than one presentation and they run on different clocks. This trips people up more often than site choice does.
| Single-dose pen | Single-patient-use KwikPen | |
|---|---|---|
| Doses per device | One | Four fixed weekly doses |
| How long it lasts | One week | Four weeks |
| Pen needle | Supplied with the device | Not included, a new one per dose |
| Rotation implication | Nothing to track beyond the site | Four sites per pen, so one pen equals one half of the cycle below |
If you are on the KwikPen, that four dose structure is useful rather than annoying: it gives the rotation a natural unit. One pen, four different spots. Two pens, eight. Then you are back where you started, on skin that has had two months to recover.
An eight week rotation cycle
Two usable areas, four spots in each. Run it in this order and the record keeps itself.
| Week | Area | Spot | KwikPen |
|---|---|---|---|
| 1 | Abdomen | Upper left, 2 in clear of the navel | Pen 1 |
| 2 | Thigh | Left front, upper half | |
| 3 | Abdomen | Upper right | |
| 4 | Thigh | Right front, upper half | |
| 5 | Abdomen | Lower left | Pen 2 |
| 6 | Thigh | Left front, lower half | |
| 7 | Abdomen | Lower right | |
| 8 | Thigh | Right front, lower half |
Two rules override the table. Never inject into skin that is bruised, tender, hard, lumpy or broken, so skip a spot whose turn has come if it is not ready and take the next one. And if someone is available to inject the back of your upper arm on a given week, that is a ninth and tenth spot you can drop into the cycle, which buys the other eight more recovery time.
Why not just alternate left and right?
Because two spots at one injection a week means each is used 26 times a year. Eight spots means roughly six times a year each. The rotation instruction exists to spread that load, and a two spot alternation barely spreads it at all.
What rotation is actually protecting you from
Not weight loss. Skin. In the pooled placebo-controlled adult trials, injection site reactions were reported in 3.2% of Mounjaro-treated patients against 0.4% on placebo. That is a low rate, and it is worth knowing what moves it.
The label reports something more interesting in the seven trial pool: injection site reactions occurred in 119 of 2,570 patients (4.6%) who developed anti-tirzepatide antibodies, and in 18 of 2,455 (0.7%) who did not. So the biggest single driver of whether you get local reactions on tirzepatide is an immune response you cannot see and cannot control, not your technique. The label also notes there was "no identified clinically significant effect of anti-tirzepatide antibodies on pharmacokinetics or effectiveness of MOUNJARO", which is the reassuring half of that finding.
What you can control is the repeated mechanical insult of hitting the same spot. That is the part rotation addresses, and it is the reason the instruction appears on every dose line of the label.
The claim to ignore: "the abdomen absorbs better"
You will find this on several Mounjaro pages, sometimes supported by a general study of small peptide absorption. It does not apply here, because tirzepatide has been measured directly. Section 12.3 of the Mounjaro prescribing information states that similar exposure was achieved in the abdomen, thigh or upper arm. The drug has an absolute bioavailability of 80%, reaches peak plasma concentration a median of 24 hours after the dose with a range of 8 to 72 hours, and has an elimination half-life of roughly 5 to 6 days.
A once-weekly drug that takes a day or more to peak and clears over the better part of a week cannot be meaningfully tuned by picking a different patch of subcutaneous fat. The abdomen-is-faster rule is real for rapid-acting insulin, and it has been copied across to GLP-1 content where it does not belong.
Making the cycle survive week five
A rotation plan fails in one specific way. Not by being wrong, but by being forgotten. By the second month, "somewhere on the right, I think" has quietly collapsed the eight spot cycle down to the two or three that are easiest to reach, and those are the ones that start to sting and lump.
This is the narrow problem Jabby exists to solve. Each dose is logged against a body map, the next spot in your cycle is proposed rather than recalled, and anything you note afterwards, soreness, a bump, a rough week, stays attached to the spot and the dose it followed. When your prescriber asks whether a reaction is tracking with a particular site or with a dose increase, that record answers it. More on the workflow in our tirzepatide injection tracking guide.
Keep an eight week cycle eight weeks long
Jabby logs every Mounjaro dose against a body map, proposes the next site, and ties any reaction back to the spot and dose that preceded it.
Download Jabby, free on the App StoreFrequently asked questions
Is it better to inject Mounjaro in the stomach or the thigh?
Neither is better for effectiveness. The label states similar exposure across the abdomen, thigh and upper arm. Most people find the abdomen easier to reach and slightly less tender because the fat layer is deeper there, but that is individual.
Can I inject Mounjaro into my arm myself?
The label describes the back of the upper arm as a site another person injects for you. It is the one area you cannot see or easily reach while injecting. Ask your prescriber before using it alone.
How often should I change the Mounjaro injection site?
Every dose. The label says "Rotate injection sites with each dose", which at once weekly means a different spot every week. You may stay in the same area as long as the spot inside it changes.
Does injecting in a different place change how well Mounjaro works?
No. Similar exposure was achieved in all three approved areas, and there is no dose adjustment associated with changing site.
What if I forget which site I used last week?
Choose a spot you are confident is not the one you used, and start a written or app-based record from that dose onward. The cycle only works if it is recorded somewhere other than memory.
Can I inject into a spot that is still slightly sore?
No. Skip it and take the next spot in the cycle. Injecting into skin that is tender, bruised, hard or broken is advised against on every GLP-1 label, and it is a good way to turn a mild reaction into a persistent one.
Does the thigh hurt more than the abdomen?
Often, yes, because the subcutaneous layer over the thigh tends to be thinner. It varies by person and by body composition, and it is a reasonable basis for choosing between the two areas since effectiveness does not differ.
Related reading
- Best GLP-1 injection site for weight loss, with the exact site wording from all four US labels side by side
- Where is the best injection site for Wegovy, and what the semaglutide label permits that the tirzepatide one does not
- Treating a tirzepatide injection site reaction, and which remedies have evidence behind them
- KwikPen pen needles, which ones fit and how many a four dose pen consumes
- Mounjaro vs Ozempic vs Wegovy if you are comparing the medications
- Tracking tirzepatide injections, dose history and site logs in one place
Sources
- MOUNJARO (tirzepatide) US prescribing information, Eli Lilly and Company. Sections 2.2 administration, 3 dosage forms, 6.1 injection site reactions, 12.3 pharmacokinetics, 12.6 immunogenicity.
- KwikPen Instructions for Use, Eli Lilly and Company, for the site selection and rotation wording and the 2 inch navel clearance.
- MOUNJARO label on DailyMed, US National Library of Medicine.
This page summarises published prescribing information for general education. It is not medical advice and gives no dosing guidance. Decisions about your dose, your device and where you inject belong to the clinician who prescribed Mounjaro. Always follow the Instructions for Use packaged with your own pen.
Jabby is free on the App Store and keeps your Mounjaro dose history, site rotation and side effects in one record.